

(19) World Intellectual Property Organization
International Bureau(43) International Publication Date
7 February 2002 (07.02.2002)

PCT

(10) International Publication Number
WO 02/10427 A1(51) International Patent Classification: C12P 19/22,
19/18

(21) International Application Number: PCT/DK01/00504

(22) International Filing Date: 17 July 2001 (17.07.2001)

(25) Filing Language: English

(26) Publication Language: English

(30) Priority Data:
PA 2000 01147 28 July 2000 (28.07.2000) DK
60225/937 17 August 2000 (17.08.2000) US(71) Applicant (for all designated States except US):
NOVOZYMES A/S [DK/DK]; Kroghshøjvej 36, DK-2880
Bagsværd (DK).

(72) Inventors: and

(75) Inventors/Applicants (for US only): NORMAN, Barrie,
Edmund [GB/DK]; Magnoliavej 5B, DK-3460 Birkerød
(DK). HENDRIKSEN, Hanne, Vang [DK/DK]; Vejle-
sevej 5A, DK-2840 Høje (DK).(74) Common Representative: NOVOZYMES A/S, Patents,
Kroghshøjvej 36, DK-2880 Bagsværd (DK).(81) Designated States (national): AE, AG, AI, AM, AT, AU,
AZ, BA, BB, BG, BR, BY, BZ, CA, CH, CN, CO, CR, CU,
CZ, DE, DK, DM, DZ, EC, EE, ES, FI, GB, GD, GE, GH,
GM, HR, HU, ID, IL, IN, IS, JP, KE, KG, KP, KR, KZ, LC,
LK, LR, LS, LT, LU, LV, MA, MD, MG, MK, MN, MW,
MX, MY, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK,
SL, TJ, TM, TR, TT, TZ, UA, UG, US, UZ, VN, YU, ZA,
ZW.(84) Designated States (regional): ARIPO patent (GH, GM,
KE, LS, MW, MZ, SD, SL, SZ, TZ, UG, ZW), Eurasian
patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European
patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE,
IT, LU, MC, NL, PT, SE, TR), OAPI patent (BF, BJ, CF,
CG, CI, CM, GA, GN, GQ, GW, ML, MR, NE, SN, TD,
TG).**Published:**

- with international search report
- before the expiration of the time limit for amending the
claims and to be republished in the event of receipt of
amendments
- entirely in electronic form (except for this front page) and
available upon request from the International Bureau

For two-letter codes and other abbreviations, refer to the "Guide-
ance Notes on Codes and Abbreviations" appearing at the begin-
ning of each regular issue of the PCT Gazette.



WO 02/10427 A1

(54) Title: METHOD FOR PRODUCING MALTOSE SYRUP BY USING A HEXOSYLTRANSFERASE

(57) Abstract: The present invention relates to a method of producing maltose syrup, wherein starch is treated with a hexosyl-transferase (E.C. 2.4.1) and then a beta-amylase and/or a maltogenic amylase, or variant thereof. The invention also relates to an intermediate product suitable as starting material in maltose production processes.

METHOD FOR PRODUCING MALTOSE SYRUP BY USING A HEXOSYLTRANSFERASE

The present invention concerns a method of production of maltose syrup, whereby starch is treated with a
5 hexosyltransferase and a beta-amylase and/or a maltogenic amylase, or variant thereof. Further, the invention also relates to a suitable starting material for the production of maltose.

BACKGROUND OF THE INVENTION

10 Maltose

Maltose is a disaccharide having the chemical structure of 4-O-alpha-D-glucopyranosyl-D-glucopyranose ($C_{12}H_{22}O_{11}$) and is the main component of maltose syrups.

15 Application of Maltose Syrups

Maltose is used to replace sucrose in a number of foodstuffs and confectionary products as well as starting product for hydrogenation to maltitol.

Maltose does not crystallize easily, in contrast to, e.g.,
20 glucose, which is able to crystallize even in the presence of impurities in high concentrations. Maltose is not able to crystallize and thus to be purified further, unless the maltose used as a starting material exhibits a purity above 90%. Also, the fact that maltose does not crystallize easily is one of the
25 reasons why maltose is a valuable raw material in the candy industry.

Maltose has also other applications, e.g., as the active component of intravenous injection liquids intended for provision of sugar for the patient and as a component in frozen deserts
30 (due to low crystallization ability of maltose), in the baking and brewing industry, and for production of maltitol, which can be used as a sweetening agent, like sorbitol, vide Glycose Sirups, Science and Technology, Elsevier Applied Science Publishers 1984, pages 117 - 135.

Thus, the purpose of the invention is to provide a method of producing maltose syrup.

DESCRIPTION OF THE INVENTION

5 The object of the present invention is to provide a method of producing high maltose syrup.

At least in the context of the present invention high maltose syrup is syrup with a maltose content of at least 80%, preferably at least 90%.

10

Traditional Methods of Producing Maltose

The starting (raw) material for maltose production processes is starch from corn, potato, sweet potato, manioc, rice, and cassava in a concentration of about 10-20% for production of
15 medical grade maltose and in the range of 20-40% for food grade maltose.

Various methods of producing maltose have been known and the purity of the maltose obtained by these methods is in the range from 75-90%. A typical example of these methods comprise heating
20 and treating a starch slurry with alpha-amylase thereby liquefying the starch and then hydrolysing the liquefied starch with beta-amylase and pullulanase (alpha-1,6-glucosidase) to afford a maltose solution, which may then be purified.

The greater part of the "impurities" in this maltose solution
25 comprises glucose and oligosaccharides, such as maltotriose and limit dextrans, which consists of three or more glucose units.

Method of the invention

The inventors of the present invention have found, that a
30 maltose syrup with a higher maltose content can be obtained - than when liquefying with an alpha-amylase - by treating a starch slurry with a hexosyltransferase (E.C. 2.4.1) followed by treatment with a beta-amylase (E.C. 3.2.1.2) and/or a maltogenic amylase, or a variant thereof.

Thus, in the first aspect the invention relates to a method of producing maltose, wherein starch is treated with

i) a hexosyltransferase (E.C. 2.4.1), and then

ii) a beta-amylase and/or a maltogenic amylase, or a variant thereof.

Preferably the method of the invention comprises the steps of:

a) treating starch with a hexosyltransferase (E.C. 2.4.1) until a product having

i) an Additional Degree of Branching (ADB) of between 10-150% has been provided if using a branching enzyme, and/or

ii) a viscosity corresponding to that of liquefied starch obtainable by treating 30% DS starch with wild type *Bacillus licheniformis* alpha-amylase until a DE in the range from 8-15, preferably DE of between 10-12, has been provided,

b) the product provided in step a) is treated with a beta-amylase and/or a maltogenic amylase, or variant thereof, and optionally

c) recovering and/or purifying maltose from the product provided in step b).

Dextrose Equivalent (DE) and Additional Degree of Branching (ADB)

The degree of branching of a starch product is determined by measuring the DE (Dextrose Equivalent) of the starch product after debranching with isoamylase (*Pseudomonas* isoamylase available from Hayashibara, Japan). The higher the DE (after debranching), the higher the degree of branching. The additional degree of branching (ADB) introduced by the hexosyltransferase is calculated as

$$\text{Additional Degree of Branching} = \frac{\text{DE} - X}{X} \times 100\%$$

X is the DE after debranching of native starch (i.e., the starting material).

Method for treating starch with hexosyltransferase

- 5 To obtain an effective enzymatic treatment of the starch, the starch may in a preferred embodiment be gelatinised. Dependent upon the heat stability of the enzyme and the gelatinisation temperature of the specific starch this can be done either in combination with enzyme treatment or prior to enzyme
- 10 treatment. Gelatinisation may be carried out either in a batch system or continuously in a jet-cooker. In lab-scale simple heating systems can be used, e.g., an oil bath, pressure cooker or autoclave. Specific reaction conditions for the subsequent enzymatic treatment or for the combined gelatinisation/enzyme
- 15 process, i.e., temperature, pH, % DS, dosage and incubation time depend upon the characteristics of the enzyme and the starch source.

- In an embodiment the starch slurry in step a) of the process of the invention is treated at 50-150°C, preferably in the
- 20 range from 50-100°C. In the case of using a 1,4-alpha-glucan branching enzyme as the hexosyltransferase the treating temperature will be in the range from 50-70°C, preferably around 65°C. In an embodiment, when using 1,4-alpha-glucan branching enzyme the starch is gelatinized first by jetting at 105°C-140°C
- 25 and then cooled to about 65°C.

In the case of 4-alpha-glucanotransferase (amylomaltases or D-enzyme) and CGTase a gelatination step is optional and may be left out. Thus, starch may be treated (incubated directly with the enzyme(s)) at from 80-100°C, preferably around 90°C.

- 30 A pullulanase may be added in step b). In general the starch (raw) starting material is a 10-50% DS starch slurry, preferably a 20-40% DS starch slurry, especially a starch slurry having around 30% DS.

The invention also relates to a product obtainable by

a) treating starch with a hexosyltransferase (E.C. 2.4.1)

i) until a product having an Additional Degree of Branching (ADB) of between 10-150% has been provided when using a branching enzyme, and/or

ii) a viscosity corresponding to that of liquefied starch obtainable by treating 30% DS starch with wild type *Bacillus licheniformis* alpha-amylase until a DE in the range from 8-15, preferably DE of between 10-12, has been provided.

The product is suitable as starting material for maltose processes. The product is stable and have a reduced tendency to retrograde and is soluble in aqueous solution.

In a further aspect the invention relates to a maltose-containing product obtainable by the method of the invention.

The product obtained this way has a maltose (DP₂) content of above 80%, preferably 85%, especially above 90%.

Further, the invention also relates to the use of the product of the invention prepared by treating starch with a hexyltransferase as starting (raw) material (substrate) for the production of maltose.

Hexosyltransferase

Examples of hexyltransferase (E.C. 2.4.1) include 1,4-alpha-Glucan branching enzyme (E.C. 2.4.1.18); 4-alpha-glucanotransferase (amylomaltases or D-enzyme) (E.C. 2.4.1.25); Cyclomaltodextrin glucanotransferase (CGTase) (E.C. 2.4.1.19).

1,4-alpha-glucan branching enzyme

In an embodiment the hexosyl transferease is 1,4-alpha-glucan branching enzyme which forms additional 1,6-glucosidic linkages of amylopectin and converts amylose into amylopectin. Amylopectin branching enzyme is frequently termed Q-enzyme.

A specifically contemplated 1,4-alpha-Glucan branching enzyme is derived from *Rhodothermus*, preferably *Rhodothermus obamensis*, especially the deposited strain *E.coli* DSM 12607 comprising the *glgB* gene from *Rhodothermus obamensis*.

5

4-alpha-glucanotransferase (amylomaltases or D-enzyme)

In an embodiment the hexosyl transferease is 4-alpha-glucanotransferase, which transfers a segment of a 1,4-alpha-D-glucan to a new 4-position in an acceptor, which may be glucose or 1,4-alpha-D-glucan. 4-alpha-glucanotransferase is often referred to as D-enzyme.

A specifically contemplated 4-alpha-glucanotransferase is derived from *Thermococcus litoralis* (Jeon, Beong-Sam, et al: 4-alpha-Glucanotransferase from the hyperthermophilic archaeon *Thermococcus litoralis* (1997). Eur.J.Biochem. 248: 171-178.)

15

CGTase

In an embodiment the CGTase or CGTase variant is derived from a strain of *Bacillus*, a strain of *Brevibacterium*, a strain of *Clostridium*, a strain of *Corynebacterium*, a strain of *Klebsiella*, a strain of *Micrococcus*, a strain of *Thermoanaerobium*, a strain of *Thermoanaerobacter*, a strain of *Thermoanaerobacterium*, a strain of *Thermoanaerobacterium*, or a strain of *Thermoaactinomyces*.

In a preferred embodiment, the CGTase or CGTase variant is derived from a strain of *Bacillus autolyticus*, a strain of *Bacillus cereus*, a strain of *Bacillus circulans*, a strain of *Bacillus circulans* var. *alkalophilus*, a strain of *Bacillus coagulans*, a strain of *Bacillus firmus*, a strain of *Bacillus halophilus*, a strain of *Bacillus macerans*, a strain of *Bacillus megaterium*, a strain of *Bacillus ohbensis*, a strain of *Bacillus stearothermophilus*, a strain of *Bacillus subtilis*, a strain of

30

Klebsiella pneumonia, a strain of *Thermoanaerobacter ethanolicus*, a strain of *Thermoanaerobacter finnii*, a strain of *Clostridium thermoamylolyticum*, a strain of *Clostridium thermosaccharolyticum*, or a strain of *Thermoanaerobacterium*
5 *thermosulfurigenes*.

In a more preferred embodiment the CGTase or CGTase variant is derived from the strain of *Bacillus sp.* strain 1011, the strain *Bacillus sp.* strain 38-2, the strain *Bacillus sp.* strain 17-1, the strain *Bacillus sp.* 1-1, the strain *Bacillus sp.* strain
10 B1019, the strain *Bacillus circulans* Strain 8, the strain *Bacillus circulans* Strain 251, or the strain *Thermoanaerobacter sp.* ATCC 53627, or mutants or variants thereof.

Contemplated CGTase variants are disclosed in WO 96/33267 (Novozymes A/S) and WO 99/15633 (Novozymes A/S), which are
15 hereby incorporated by reference.

A commercially available CGTase product is Toruzyme® from Novozymes A/S.

Beta-Amylase

20 Examples of beta-amylases (E.C. 3.2.1.2) include crop beta-amylases, such as barley beta-amylases, wheat beta-amylases, soybean beta-amylases, and beta-amylases derived from *Bacillus sp.*, such as the beta-amylase disclosed in US patent no. 4,970,158 (Novozymes A/S).

25 Commercially available beta-amylases include Spezyme® BBA and Spezyme® DBA from Genencor Int.

Pullulanase

30 Examples of pullulanases (E.C. 3.2.1.41) include a thermostable pullulanase from, e.g., *Pyrococcus* or a protein engineered pullulanase from, e.g., a *Bacillus* strain such as *Bacillus acidopullulyticus* or *Bacillus deramificans* (e.g., the *Bacillus*

deramificans pullulanase with GeneBank accession number Q68699).

Commercially available pullulanases include Promozyme® D from Novozymes A/S and Optimax® from Genencor Int.

5

Maltogenic Amylase

A maltogenic amylase (E.C. 3.1.133) hydrolyses 1,4-alpha-D-glucosidic linkages in polysaccharides so as to remove successive alpha-maltose residues from the non-reducing ends of the chains. A maltogenic amylase acts on starch and related polysaccharides and oligosaccharides.

An Example of a suitable maltogenic amylase is the maltogenic amylase produced by *Bacillus stearothermophilus* C599 disclosed in EP patent no. 120,693 (Novo Industri A/S). Contemplated maltogenic amylase variants are disclosed in WO 99/43794 and WO 99/43793, which are thereby incorporated by reference.

A commercially available maltogenic amylase is sold under the tradename Maltogenase® (Novozymes A/S, Denmark).

MATERIALS & METHODS

Branching enzyme: *Rhodothermus obamensis* D-enzyme disclosed in WO 00/58445 (Novozymes A/S, Denmark).

Spezyme® BBA 1500 is a barley beta-amylase (available from Genencor Int., USA).

Promozyme® D is a pullulanase derived from a strain of *Bacillus* (available from Novozymes A/S, Denmark)

Isoamylase: *Pseudomonas* isoamylase (available from Hayashibara, Japan).

Toruzyme® is a heat-stable cyclomaltodextrin glucanotransferase (CGTase) derived from a strain of *Thermoanaerobacter* (available on request from Novozymes A/S, Denmark).

Termamyl® LC is an alpha-amylase derived from *Bacillus licheniformis* (available on request from Novozymes A/S, Denmark)

Maltogenase® (available from Novozymes A/S, Denmark).

Wild type *Bacillus licheniformis* alpha-amylase is disclosed as SEQ ID NO: 4 in WO 99/19467. (Novozymes A/S, Denmark).

5 Methods

Beta-amylase activity (DP°)

The activity of Spezyme® BBA 1500 is expressed in Degree of Diastatic Power (DP°). It is the amount of enzyme contained in 0.1 ml of a 5% solution of the sample enzyme preparation that
10 will produce sufficient reducing sugars to reduce 5 ml of Fehling's solution when the sample is incubated with 100 ml of substrate for 1 hour at 20°C (68°F).

Pullulanase activity (New Pullulanase Unit Novo (NPUN))

15 One new Pullulanase Unit Novo (NPUN) is a unit of endo-pullulanase activity and is measured relative to Novozymes standard made on 0.7% Red Pullulan, 40°C, pH 4.5, 30 minutes reaction time. A detailed description of the analysis method is available on request (SOP No.: EB-SM.0420.02/01).

20

Branching Enzyme Activity

Branching Enzyme activity is determined according to a modified version of the procedure described by Takata et al., Applied and Environmental Microbiology (1994), p. 3097 (assay
25 A):

20 micro l enzyme solution is mixed with 50 micro litre water and 50 micro litre substrate solution and incubated for 30 minutes at testing temperature. The substrate solution is 0.1% type III amylose dissolved in Tris buffer. The reaction is
30 terminated by the addition of 2 ml of iodine reagent. Iodine reagent is made daily from 0.5 ml of stock solution (0.26 g of I₂ and 2.6 g of KI in 10 ml of water) mixed with 0.5 ml of 1 N HCl and diluted to 130 ml. The mixture is incubated for 15 minutes at room temperature to stabilize the colour. Activity

is measured as difference in A660 between a tested sample and a control in which cell extract is replaced by water. One unit of branching enzyme activity is defined as the amount of enzyme that can decrease the A660 of the amylose-iodine complex by 1% per minute at 60°C, pH 7.0.

Method for treating starch with hexosyltransferase

a) when using Branching Enzyme the following procedure may be used:

10 A 10-30% DS, pH 7-8, starch suspension is gelatinised in a jet-cooker or an autoclave. The slurry is then cooled to 60-70°C and branching enzyme added. When the specified conversion is reached (total time will depend upon dosage) the reaction is terminated by heating to 100°C for 15 minutes.

15

b) for Glucanotransferase or CGT'ase preparation can be made as follows:

A 30% DS, pH 5-7, starch suspension is prepared and enzyme added. The suspension is then heated to 70-90°C and incubated for 4-24h. When the specified conversion is reached (total time will depend upon dosage) the reaction is terminated by heating to 140°C for 5-15 minutes.

EXAMPLES

25

Example 1

Production of maltose

30 30% DS potato starch substrate liquefied with Branching Enzyme was prepared. The starch slurry was clear and stable. The starch slurry was then treated with beta-amylase (1 DP°/g DS) and pullulanase (1 NPUN/g DS) at 60°C, pH 5.0.

After 72 hours incubation 89% maltose was obtained. In comparison to this only 75% maltose was obtained under identical conditions using Termamyl LC DE 10 maltodextrin.

Claims

1. A method of producing maltose, wherein starch is treated with
 - i) a hexosyltransferase (E.C. 2.4.1), and then
 - 5 ii) a beta-amylase (E.C. 3.2.1.2) and/or a maltogenic amylase (E.C. 3.2.1.133), or variant thereof.
2. The method of claim 1, comprising the steps of:
 - a) treating starch with a hexosyltransferase (E.C. 2.4.1) un-
10 til a product having
 - i) an Additional Degree of Branching (ADB) of between 10-150% has been provided if using a branching enzyme, and/or
 - ii) a viscosity corresponding to that of liquefied starch ob-
tainable by treating 30% DS starch with wild type *Bacillus*
15 *licheniformis* alpha-amylase until a DE in the range from 8-15, preferably DE of between 10-12, has been provided,
 - b) the product provided in step a) is treated with a beta-amylase and/or a maltogenic amylase, or variant thereof, and optionally
 - 20 c) recovering and/or purifying maltose from the product provided in step b).
3. The method of claim 2 wherein starch in step a) is treated at 50-150°C, preferably in the range from 50-100°C.
25
4. The method of claim 1 or 2, wherein further a pullulanase is added in step b).
5. The method of any of claims 1-4, wherein a 10-50% DS starch
30 slurry, preferably a 20-40% DS, especially around 30% DS starch slurry is used as the starting material.
6. The method of claim 1, wherein the hexyltransferase (E.C. 2.4.1.) is one or more of the enzymes selected from the group

consisting of 1,4-alpha-Glucan branching enzyme (E.C. 2.4.1.18); 4-alpha-glucanotransferase (amylomaltases or D-enzyme) (E.C. 2.4.25); Cyclomaltodextrin glucanotransferase (CGTase) (E.C. 2.4.1.19).

5

7. The method of claims 1-6, wherein the starch in step a) is treated with a combination of D-enzyme and a maltogenic amylase or variant thereof.

10 8. The method of claim 1, wherein the beta-amylase (E.C. 2.4.1.2) is barley beta-amylase.

9. The method of claim 1, wherein the pullulanase is a *Bacillus pullulanase*.

15

10. The method of claim 6, wherein the 1,4-alpha-Glucan branching enzyme (E.C. 2.4.1.18) is derived from *Rhodothermus*, preferably *Rhodothermus obamensis*.

20 11. The product obtainable by treating starch with a hexosyltransferase (E.C. 2.4.1) until a product having
i) an Additional Degree of Branching (ADB) of between 10-150% has been provided if using a branching enzyme, and/or
ii) a viscosity corresponding to that of liquefied starch ob-
25 tainable by treating 30% DS starch with wild type *Bacillus licheniformis* alpha-amylase until a DE in the range from 8-15, preferably DE of between 10-12, has been provided.

12. The product of claim 11, wherein the hexosyltransferase
30 (E.C. 2.4.1) is one or more of the enzymes selected from the group consisting of 1,4-alpha-Glucan branching enzyme (E.C. 2.4.1.18); 4-alpha-glucanotransferase (amylomaltases or D-enzyme) (E.C. 2.4.25); Cyclomaltodextrin glucanotransferase (CGTase) (E.C. 2.4.1.19).

13. The method of claim 12, wherein the 1,4-alpha-Glucan branching enzyme (E.C. 2.4.1.18) is derived from *Rhodothermus*, preferably *Rhodothermus obamensis*, especially the deposited
5 strain *E.coli* DSM 12607 comprising the *gigB* gene from *Rhodothermus obamensis*.

14. The syrup product obtainable by the method of any of claims 1-10.

10

15. The syrup product of claim 14, wherein the maltose (DP₂) content is above 80%, preferably 85%, especially above 90%.

16. Use of a product of any of claims 11-13, as starting material (substrate) for the production of maltose.
15

17. Use according to claim 16, wherein a portion of the product is used as starting material (substrate) for the production of maltose.

20

A. CLASSIFICATION OF SUBJECT MATTER
IPC 7 C12P19/22 C12P19/18

According to International Patent Classification (IPC) or to both national classification and IPC

B. FIELDS SEARCHED

Minimum documentation searched (classification system followed by classification symbols)
IPC 7 C12P

Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched

Electronic data base consulted during the international search (name of data base and, where practical, search terms used)

BIOSIS, EMBASE, EPO-Internal

C. DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 92 13962 A (NOVONORDISK AS) 20 August 1992 (1992-08-20) page 4, line 1 - line 3 page 4, line 17 - line 18	11-13
Y	---	1-10, 14-17
Y	EP 0 905 256 A (ROQUETTE FRERES) 31 March 1999 (1999-03-31) page 6; example 1	1-10, 14-17
X	EP 0 690 170 A (AVEBE COOP VERKOOP PROD) 3 January 1996 (1996-01-03) page 3, line 42 - line 43 page 6, line 26 - line 27 ---	11-13

-/--

☒ Further documents are listed in the continuation of box C.

☒ Patent family members are listed in annex.

* Special categories of cited documents:

- "A" document defining the general state of the art which is not considered to be of particular relevance
- "E" earlier document but published on or after the international filing date
- "I" document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)
- "O" document referring to an oral disclosure, use, exhibition or other means
- "P" document published prior to the international filing date but later than the priority date claimed

"I" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention

"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone

"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art

"A" document member of the same patent family

Date of the actual completion of the international search

23 November 2001

Date of mailing of the international search report

21.12.01

Name and mailing address of the ISA

European Patent Office, P.B. 5818 Patentlaan 2
NL - 2280 HV Rijswijk
Tel. (+31-70) 340-2040, Tx. 31 651 epo nl
Fax: (+31-70) 340-9018

Authorized officer

Anna Björklund

INTERNATIONAL SEARCH REPORT

International Application No.

PCT/DK 01/00504

C.(Continuation) DOCUMENTS CONSIDERED TO BE RELEVANT

Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
X	WO 98 15347 A (AVEBE COOP VERKOOP PROD) 16 April 1998 (1998-04-16) page 8; example 2	11-13
A	-----	7

INTERNATIONAL SEARCH REPORT

International application No.
PCT/DK 01/00504

Box I Observations where certain claims were found unsearchable (Continuation of item 1 of first sheet)

This International Search Report has not been established in respect of certain claims under Article 17(2)(a) for the following reasons:

1. ☐ Claims Nos.:
because they relate to subject matter not required to be searched by this Authority, namely:

2. ☒ Claims Nos.: **11-13, 16, 17**
because they relate to parts of the international Application that do not comply with the prescribed requirements to such an extent that no meaningful international Search can be carried out, specifically:
see FURTHER INFORMATION sheet PCT/ISA/210

3. ☐ Claims Nos.:
because they are dependent claims and are not drafted in accordance with the second and third sentences of Rule 6.4(a).

Box II Observations where unity of invention is lacking (Continuation of item 2 of first sheet)

This International Searching Authority found multiple inventions in this international application, as follows:

1. ☐ As all required additional search fees were timely paid by the applicant, this International Search Report covers all searchable claims.

2. ☐ As all searchable claims could be searched without effort justifying an additional fee, this Authority did not invite payment of any additional fee.

3. ☐ As only some of the required additional search fees were timely paid by the applicant, this International Search Report covers only those claims for which fees were paid, specifically claims Nos.:

4. ☐ No required additional search fees were timely paid by the applicant. Consequently, this International Search Report is restricted to the invention first mentioned in the claims; it is covered by claims Nos.:

Remark on Protest

- ☐ The additional search fees were accompanied by the applicant's protest.
- ☐ No protest accompanied the payment of additional search fees.

FURTHER INFORMATION CONTINUED FROM PCT/ISA/ 210

Continuation of Box I.2

Claims Nos.: 11-13,16,17

Present claims 11-13 and 16,17 relate to a product defined by reference to a desirable characteristic or property, namely an additional degree of branching of between 10-150% and/or a viscosity corresponding to that of liquefied starch obtainable by treating 30% DS starch with wild type *Bacillus licheniformis* alpha-amylase until a DE between 8-15 is reached.

The claims cover all products having this characteristic or property, whereas the application provides support within the meaning of Article 6 PCT and/or disclosure within the meaning of Article 5 PCT for only a very limited number of such products. In the present case, the claims so lack support, and the application so lacks disclosure, that a meaningful search over the whole of the claimed scope is impossible. Independent of the above reasoning, the claims also lack clarity (Article 6 PCT). An attempt is made to define the product by reference to a result to be achieved. Again, this lack of clarity in the present case is such as to render a meaningful search over the whole of the claimed scope impossible. Consequently, the search has been carried out for those parts of the claims which appear to be clear, supported and disclosed, namely those parts relating to treating starch with hexosyltransferases in general, and specifically the hexosyltransferases given in claim 12.

Claim 13 is unclear since it is a method claim, but refers to the product claim 12. However, claim 13 has been treated as being a product claim.

The applicant's attention is drawn to the fact that claims, or parts of claims, relating to inventions in respect of which no international search report has been established need not be the subject of an international preliminary examination (Rule 66.1(e) PCT). The applicant is advised that the EPO policy when acting as an International Preliminary Examining Authority is normally not to carry out a preliminary examination on matter which has not been searched. This is the case irrespective of whether or not the claims are amended following receipt of the search report or during any Chapter II procedure.

INTERNATIONAL SEARCH REPORT

Information on patent family members

International Application No.

PCT/DK 01/00504

Patent document cited in search report		Publication date		Patent family member(s)	Publication date
WO 9213962	A	20-08-1992	WO JP	9213962 A1 6505149 T	20-08-1992 16-06-1994
EP 0905256	A	31-03-1999	FR AU BR CA EP JP US	2769023 A1 8704798 A 9803973 A 2248439 A1 0905256 A1 11206325 A 6284498 B1	02-04-1999 15-04-1999 28-03-2000 26-03-1999 31-03-1999 03-08-1999 04-09-2001
EP 0690170	A	03-01-1996	NL AT DE DE DK EP ES	9401090 A 196172 T 69518702 D1 69518702 T2 690170 T3 0690170 A1 2151575 T3	01-02-1996 15-09-2000 12-10-2000 01-02-2001 16-10-2000 03-01-1996 01-01-2001
WO 9815347	A	16-04-1998	NL AU EP JP WO PL	1004214 C2 4474097 A 0932444 A1 2001501670 T 9815347 A1 332627 A1	10-04-1998 05-05-1998 04-08-1999 06-02-2001 16-04-1998 27-09-1999